Posaconazole tablet formulation at 400 milligrams daily achieves desired minimum serum concentrations in adult patients with a hematologic malignancy or stem cell transplant

Aaron N. Pham, Joseph Bubalo, James S. Lewis

    Research output: Contribution to journalArticle

    5 Scopus citations


    We describe our experience using the posaconazole 400-mg delayed-release tablet formulation once daily in 20 patients with hematologic malignancy or hematopoietic stem cell transplant who were unable to attain prespecified target minimum serum (trough) concentrations for treatment or prophylaxis of invasive fungal infection. The higher dose allowed the majority of patients to achieve prespecified target trough concentrations without incurring additional toxicities.

    Original languageEnglish (US)
    Pages (from-to)6945-6947
    Number of pages3
    JournalAntimicrobial Agents and Chemotherapy
    Issue number11
    StatePublished - Nov 1 2016


    ASJC Scopus subject areas

    • Pharmacology
    • Pharmacology (medical)
    • Infectious Diseases

    Cite this